Cramer says CyberArk Software is doing well but he's avoiding Clovis Oncology.
Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.
Here's a technical look at how to trade some of the most active stocks on the market right now.
The FDA granted accelerated approval for Clovis Oncology's (CLVS) rucaparib drug.